title: A novel microcrystalline tyrosine-adsorbed, mite-allergoid subcutaneous immunotherapy: 1-year follow-up report.
abstract: A 1-year follow-up study comparing the safety and tolerability of the dosing schedules, satisfaction and effectiveness of a novel microcrystalline tyrosine-adsorbed mite (Dermatophagoides pteronyssinus)-allergoid subcutaneous immunotherapy (Acarovac Plus™) in 30 adult patients (18-65 years) with allergic rhinitis and/or asthma.
  
  
  
  The effectiveness of the product was assessed by nasal provocation test measuring peak nasal inspiratory flow/symptoms, in vitro immunologic changes (IgE, IgG4 and IL-10) and Treatment Satisfaction Questionnaire for Medication.
  
  
  
  No adverse events were reported during dosing schedules. Significant decreases in symptom scores and drop of peak nasal inspiratory flow in follow-up visits (4 weeks and 1 year) were recorded. Significant increases in IgG4-specific antibody titers and IL-10 were exhibited.
  
  
  
  Significant decreases in clinical symptoms and immunological parameters were observed, accompanying a high level of patient satisfaction and tolerance.
authors.affiliation: Unitat d'Al.lèrgia. Hospital Universitari Germans Trias Pujol, Badalona, Spain.
authors.forename: Albert
authors.initials: A
authors.lastname: Roger
authors.affiliation: Unitat d'Al.lèrgia. Hospital Universitari Germans Trias Pujol, Badalona, Spain.
authors.forename: Nathalie
authors.initials: N
authors.lastname: Depreux
authors.affiliation: Unitat d'Al.lèrgia. Hospital Universitari Germans Trias Pujol, Badalona, Spain.
authors.forename: Yanina
authors.initials: Y
authors.lastname: Jurgens
authors.affiliation: Unitat d'Al.lèrgia. Hospital Universitari Germans Trias Pujol, Badalona, Spain.
authors.forename: Aina T
authors.initials: AT
authors.lastname: Serra
authors.affiliation: Allergy Therapeutics Plc, Dominion Way, Worthing, BN14 8SA, UK.
authors.forename: Matthew D
authors.initials: MD
authors.lastname: Heath
authors.affiliation: Allergy Therapeutics Iberica S.L. Carrer de Joan XXIII, 15, 08950 Esplugues de Llobregat, Barcelona, Spain.
authors.forename: Gloria
authors.initials: G
authors.lastname: Garcia
authors.affiliation: Allergy Therapeutics Plc, Dominion Way, Worthing, BN14 8SA, UK.
authors.forename: Murray A
authors.initials: MA
authors.lastname: Skinner
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000818:Animals; D039741:Antigens, Dermatophagoides / Q000737:chemistry / Q000627:therapeutic use*; D001249:Asthma / Q000276:immunology / Q000628:therapy*; D040002:Dermatophagoides pteronyssinus / Q000276:immunology; D003888:Desensitization, Immunologic / Q000379:methods*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007108:Immune Tolerance; D007073:Immunoglobulin E / Q000097:blood; D016753:Interleukin-10 / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D065631:Rhinitis, Allergic / Q000276:immunology / Q000628:therapy*; D016896:Treatment Outcome; D014443:Tyrosine / Q000737:chemistry; D055815:Young Adult
chemical_list: D039741:Antigens, Dermatophagoides; C508609:IL10 protein, human; D016753:Interleukin-10; D007073:Immunoglobulin E; D014443:Tyrosine
keywords: Acarovac Plus™; Dermatophagoides pteronyssinus; allergen; allergic rhinitis; allergoid; cluster; conventional; immunotherapy; nasal challenge test; subcutaneous